Puma Biotechnology Inc. (NYSE:PBYI) had its price target upped by stock analysts at Credit Suisse Group AG from $54.00 to $111.00 in a research report issued to clients and investors on Thursday. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Credit Suisse Group AG’s price objective points to a potential upside of 63.31% from the company’s current price.

A number of other brokerages also recently weighed in on PBYI. JPMorgan Chase & Co. set a $89.00 price target on shares of Puma Biotechnology and gave the company a “buy” rating in a research report on Tuesday. Citigroup Inc. set a $88.00 price target on shares of Puma Biotechnology and gave the company a “buy” rating in a research report on Tuesday. Stifel Nicolaus upgraded shares of Puma Biotechnology from a “hold” rating to a “buy” rating and increased their price target for the company from $61.00 to $88.00 in a research report on Wednesday. Vetr downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “strong sell” rating and set a $39.50 price target on the stock. in a research report on Wednesday, August 10th. Finally, Zacks Investment Research upgraded shares of Puma Biotechnology from a “hold” rating to a “buy” rating and set a $51.00 price target on the stock in a research report on Friday, August 12th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. Puma Biotechnology currently has an average rating of “Buy” and a consensus target price of $68.56.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Shares of Puma Biotechnology (NYSE:PBYI) opened at 67.97 on Thursday. Puma Biotechnology has a 52-week low of $19.74 and a 52-week high of $94.93. The company’s market capitalization is $2.21 billion. The firm has a 50-day moving average of $55.30 and a 200 day moving average of $39.51.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/puma-biotechnology-inc-pbyi-price-target-raised-to-111-00-at-credit-suisse-group-ag.html

Puma Biotechnology (NYSE:PBYI) last announced its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.18) by $1.01. On average, analysts anticipate that Puma Biotechnology will post ($8.12) EPS for the current year.

A number of hedge funds have recently made changes to their positions in the company. Northern Capital Management LLC increased its stake in shares of Puma Biotechnology by 1.2% in the second quarter. Northern Capital Management LLC now owns 16,288 shares of the biopharmaceutical company’s stock valued at $485,000 after buying an additional 190 shares during the period. Profund Advisors LLC increased its stake in shares of Puma Biotechnology by 1.6% in the second quarter. Profund Advisors LLC now owns 12,706 shares of the biopharmaceutical company’s stock valued at $379,000 after buying an additional 202 shares during the period. Teacher Retirement System of Texas increased its stake in shares of Puma Biotechnology by 13.7% in the second quarter. Teacher Retirement System of Texas now owns 3,848 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 465 shares during the period. BlackRock Group LTD increased its stake in shares of Puma Biotechnology by 2.1% in the second quarter. BlackRock Group LTD now owns 30,255 shares of the biopharmaceutical company’s stock valued at $902,000 after buying an additional 633 shares during the period. Finally, Franklin Street Advisors Inc. NC increased its stake in shares of Puma Biotechnology by 3.0% in the second quarter. Franklin Street Advisors Inc. NC now owns 34,025 shares of the biopharmaceutical company’s stock valued at $1,014,000 after buying an additional 980 shares during the period. Hedge funds and other institutional investors own 97.53% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent.

5 Day Chart for NYSE:PBYI

Receive News & Ratings for Puma Biotechnology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.